I Direct. nstinct. July 13, 2017

Similar documents
I Direct. nstinct. September 19, 2017

I Direct. nstinct. March 27, 2018

I Direct. nstinct. July 10, 2017

I Direct. nstinct. February 7, 2018

I Direct. nstinct. January 4, 2018

I Direct. nstinct. November 27, 2017

I Direct. nstinct. November 27, 2017

Singer India (SININ) Focus on tapping small appliances segment. Management Meet Note. ICICI Securities Ltd Retail Equity Research.

D-Link India (DLILIM) 105

Lumax Industries (LUMIND)

Monte Carlo Fashions (MONCAR) 580

Schaeffler India (FAGBEA) 4800

PC Jeweller (PCJEW) 417 Stepping up store expansion via small store s. Management Meet Note. ICICI Securities Ltd Retail Equity Research

Wabco India (WABTVS) Having a safe and brake free ride! Management Meet Note. ICICI Securities Ltd Retail Equity Research.

Bajaj Finserv (BAFINS) 4375

Bajaj Finance (BAJAF) 5498

Praj Industries (PRAIN)

Bajaj Finserv (BAFINS) 5443

Bajaj Finserv (BAFINS) 3130

Cement. Pet coke ban to dent margins in short-term. Sector Update. ICICI Securities Ltd Retail Equity Research. November 20, 2017

Reliance Capital (RELCAP) 549

Varun Beverages (VARBEV) 481

Arbitrage Opportunity in Wipro buyback

IndusInd Bank (INDBA) 1717

Saregama India (GRACOM) 315

Stock Trader - Power Grid

Stock Trader: Budget Beneficiary Stock Larsen & Toubro

Stock Trader - Focus on Budget: Power Grid

Emmbi Industries (EMMPOL)

Reliance Housing Finance

Wim Plast Ltd (WIMPLA) 1320

DCB Bank (DCB) 208. Healthy fundamentals priced in. Company Update. ICICI Securities Ltd Retail Equity Research. June 13, 2017

Mayur Uniquoters (MAYUNI)

Bodal Chemicals (BODCHE)

Stock Trader: ONGC. Research Analysts.

Quant Picks. Quant Pick

Power Finance Corporation Floor Price 254

Sovereign Gold Bonds. Better option to invest in gold... Gold Bond. Gold back in limelight. July 15, 2016

Consumer Discretionary Thematic 6.0 : Buy Page Industries

Stock Trader - Canara Bank: Focus on Budget

Reliance Capital (RELCAP)

April 22, Research Analyst

October 4, Quant Pick. Research Analyst

Sovereign Gold Bonds. Attractive option to invest in gold... Gold Bond. Gold back in limelight. February 24, 2017

Quant Pick Buy Axis Bank

Bank of Baroda (BANBAR) 156

Quant Pick: Punjab National Bank

Oil & Gas Thematic. Quant Pick

Graphite Electrodes. Good times to continue... Sector Update. ICICI Securities Ltd Retail Equity Research. January 3, 2018

GE Shipping (GESHIP) Striking valuation. Result Update. Rs 262 WHAT S CHANGED. Valuation. February 8, Rating matrix.

State Bank of India (STABAN) 335

Allahabad Bank (ALLBAN): Down trend line breakout after base formation

Stocks with high h short build-up likely l candidates for short covering amid recent FPI guidelines

Stocks on the move. Scrip I-Direct Code Action Target Stoploss Upside Bharti Airtel BHAAIR Buy in the range of

MPS (MACIN) 740. Uncomplicated. anagement Meet Note. ICICI Securities Ltd Retail Equity Research. December 16, 2014

Monthly Corporate Action Tracker

Biocon (BIOCON) Back on track. Result Update WHAT S CHANGED. ICICI Securities Ltd Retail Equity Research. October 21, 2011

Gladiator Stocks. Scrip I-Direct Code Action Target Stoploss Upside Tata Power TATPOW Buy in the range of

Gladiator Stocks: Reliance Industries

Gladiator Stocks: Rallis India

Research Analysts

Research Analysts

Union Bank of India (UNIBAN)

Precision Camshaft. Pricing looks imprecise... IPO Review. Price band ICICI Securities Ltd Retail Equity Research. Key Investment rationale

Research Analysts. December 3, 2015

Gladiator Stocks. Research Analysts. May 3, Cummins India CUMIND Buy in the range of

Equity Advised Portfolio Service (EAPS) External Circulation Permitted January Monthly Update

Research Analysts. March 18, Larsen & Tourbo LARTOU Buy in the range of

Gladiator Stocks. Federal-Mogul Goetze (India) Ltd. FEDGOE Buy in the range of

UltraTech Cement (ULTCEM)

KPIT Cummins Infosystems (KPISYS)

Cummins Deal Team India (CUMIND): At Your Faster Service retracement signals maturity of consolidation

Nestle India Ltd. RESULT UPDATE

Star Ferro & Cement (STAFER) 113

ITC Ltd. RESULT UPDATE 27th October, 2017

Hindustan Unilever Ltd.

SP Apparels Ltd (SPAPP)

Symphony Ltd. RESULT UPDATE 31st October 2017

Graphite India (CAREVE) 110

Astral Poly Technik (ASTPOL)

PNC Infratech. IPO Review. Price band ICICI Securities Ltd Retail Equity Research. Investment Rationale Experienced, established EPC player

Gladiator Stocks. Gateway Distriparks GATDIS Buy in the range of %

Tata Consultancy Services

Metals & Mining. Chinese steel production on declining trend. Monthly Update. ICICI Securities Ltd Retail Equity Research.

Motherson Sumi (MOTSUM) 323

Derivatives Monthly Outlook Nifty to consolidate with major hurdle at 10800

Derivatives Thematic Report

Bharti Airtel (BHATE) 369

Colgate-Palmolive India Ltd.

Banking. New MCLR guidelines marginally impact NIM. Event Update. ICICI Securities Ltd Retail Equity Research. December 18, 2015

Mahanagar Gas (MAHGAS) 985

Ahluwalia Contracts (India)

Simplex Infrastructure (SIMCON)

Prabhat Dairy Ltd. RESULT UPDATE 8th June, 2018

Balanced Funds. Mix of stability and performance. Mutual Funds. Robust long term performance track record

Graphite India (CAREVE) 454

Taj GVK Hotels (TAJGVK) 167

Stock Trader: HDFC Bank

Suzlon Energy Ltd RESULT UPDATE 16th August, 2017

Fineotex Chemical Ltd

Transcription:

I Direct nstinct July 13, 2017

I-direct Instinct Key risks to investing in I-direct Instinct It is a quick pitch note, which captures the essence of an idea in brief Instinct idea may be based on management interaction or some immediate triggers that may have a positive impact on the future of the company Target price is based on forward estimates, which will be published along with Detailed Coverage Report or Nano Nivesh report as the case may be The intent is to capture price action by coming out with a gist, which may or may not be an interim report between management interaction and publication of the final report The fair value of I-direct Instinct stocks is subject to expected growth potential in the future. Though due diligence has been done to a fair extent, the actualisation of growth still has a degree of uncertainty attached to it. Customers are advised to allocate a small proportion of their investible income to these stocks and diversify well ICICI Securities Ltd Retail Equity Research

I-direct Instinct Rating Matrix Rating : Buy Target : 1054-1082 Target Period : 12-15 months Potential Upside : 18-21% Stock Data Particular Amount Market Capitalization 3493 crore Total Debt (FY17) 25 crore Cash and Investments (FY17) 470 crore EV ( Crore) 3048 crore 52 week H/L 930 / 774 Equity capital 39 crore Face value ( ) 10 MF Holding (%) 2.4 FII Holding (%) 7.9 Price Movement 1200 1000 800 600 400 200 0 Jul-14 Oct-14 Jan-15 Apr-15 Research Analyst Jul-15 Oct-15 ZWL (LHS) Jan-16 Apr-16 Sanjay Manyal sanjay.manyal@icicisecurities.com Jul-16 Tejashwini Kumari tejashwini.kumari@icicisecurities.com Oct-16 Jan-17 Nifty (RHS) Apr-17 Jul-17 12000 10000 8000 6000 4000 2000 0 July 13, 2017 Zydus Wellness (ZWL) is a part of the Zydus Cadila Group, operating in the health and wellness space. It operates in three categories under four key brands a) sugar substitute (Sugar Free), b) health foods (Nutralite and Actilife) and c) skin care (Everyuth). It has two manufacturing facilities, one in Gujarat (mainly for Nutralite) & other in Sikkim (for Sugar Free & Everyuth). ZWL enjoys market leadership in a majority of categories in which it operates, viz. Sugar Free (93.6% market share), Nutralite (39.8% market share) & Everyuth Peel-off (92.1% market share). Triggers Leadership position and brand renovation to aid growth: Though ZWL has been able to maintain its leadership position in Sugar Free at 93.6% in FY17, the category suffered slower growth on account of content and health benefit apprehensions. ZWL is now promoting the category via media campaigns & celebrity endorsements and have launched a natural variant (Sugar Free Stevia) also. Nutralite and Everyuth (facewash and scrub), in contrast, lost significant market share over the years, mainly due to competition. ZWL has taken measures to aid the growth and gain market share. For Nutralite, it has started pushing the product in the B2B market & roped in Sanjeev Kapoor as brand ambassador to support the same. Moreover, for the Everyuth portfolio, ZWL has revamped the facewash category and has new launches in the pipeline to aid volume (details in Exhibit 2) Strong financials despite stiff competitive environment: Though the company has witnessed a muted topline in the recent past mainly due to a slowdown in the Everyuth and Nutralite product portfolio, it has continued to enjoy one of the highest gross and operating margins in the FMCG space. In FY17, it clocked 69.2% gross margin and 23.0% operating margin. Further, ZWL enjoys a lower tax rate in its manufacturing unit in Sikkim and is expected to remain low for the next two years. Additionally, being cash rich ( 440 crore in FY17), the company intends to explore options to grow inorganically in addition to focus on organic growth. Risks: A key risk to our call is any further market share loss in the aforesaid categories despite various initiatives undertaken by ZWL. Valuation & Outlook We recommend BUY on ZWL, valuing it at a target PE range of 37-38x on a trailing basis and arrive at a target price of 1054-1082/share with an investment horizon of 12-15 months. Exhibit 1: Strong clientele base (Year-end March) FY13 FY14 FY15 FY16 FY17 P&L Net sales ( crore) 388.0 403.6 430.7 396.7 430.6 EBITDA ( crore) 96.6 84.9 99.9 91.3 99.1 Net Profit ( crore) 96.9 96.4 108.2 103.3 111.3 Balance Sheet Equity ( crore) 39.1 39.1 39.1 39.1 39.1 Net worth ( crore) 256.5 325.6 406.0 478.6 557.2 Ratios RoNW (%) 37.9 29.6 26.8 21.6 19.6 RoCE (%) 41.6 31.4 29.0 23.7 18.4 ROIC (%) 164.1 179.8 179.4 149.4 328.7 Asset turnover (x) 1.5 1.2 1.0 0.8 0.7 Earnings per share ( ) 24.8 24.7 27.7 26.4 28.5 Dividend per share ( ) 6.0 6.0 6.0 6.5 6.5 Source: Company, Capitaline, ICICIdirect.com Research Zydus Wellness (ZYDWEL) 894 ICICI Securities Ltd Retail Equity Research

Exhibit 2: Product description Issues and steps undertaken for revival and growth Product Description Issues Solution Available in three sub-brands - Sugar Free Gold (made The category suffered slow growth due to various Company now taking steps to boost growth by from Aspartame a protein derivative), Sugar Free apprehensions among customers regarding the chemical widening the user base of Sugar Free from a set of Natura (made from Sucralose zero calorie sweeteners) composition and health benefits of the category diabetic patients to health conscious people and Sugar Free Stevia (made from leaves of plant called Stevia) Available in pellets, powder & liquid drops format Launched a new natural version, Sugar Free Stevia, Sugar Free made of leaves of plant named Stevia Aspiring to transform into a FMCG product from an OTC product and hence, aggressively advertising with differentiated benefits (health consciousness) and has roped in Parineeti Chopra for the same Actively undertaking consumer promotions in order to educate and engage them towards the health benefits of the category Everyuth Naturals Present in facewash, scrub and peel off categories Facing pressure over the last few years, mainly in the facewash and scrub categories where competition has increased significantly with the entrance of a number of players It has invested heavily in brand building of the Everyuth category as whole. In order to revive the facewash category, ZWL has revamped and launched the face wash category with contemporary packaging and improved benefits. Also, It has extended the portfolio towards natural versions tulsi and turmeric Peel off category itself has been de-growing for last few years (ZWL has, however, maintained its leadership position with 92.1% market share) ZWL is trying to revive the scrub and peel off categories and has a pipeline of new launches in these categories Margarine, positioned as a healthy alternative to butter Category itself has been witnessing declining trend ZWL has started taking initiatives to push the product in the B2B segment and has roped in Sanjeev Kapoor as the brand ambassador for the same and has witnessed strong traction in volumes in FY17 Nutralite Cholesterol Free, has no Trans Fats and enriched with Omega-3. Source: Company, ICICIdirect.com Research 75% of this product category is catered to institutional segment and face stiff competition from unorganised players To meet the taste palates of the India retail consumers, company has launched two flavors, Garlic Oregano and Pudina Coriander Company has developed a pan-india dedicated network to handle cold-chain products ICICI Securities Ltd Retail Equity Research Page 2

RATING RATIONALE ICICIdirect.com endeavours to provide objective opinions and recommendations. ICICIdirect.com assigns ratings to its stocks according to their notional target price vs. current market price and then categorises them as Strong Buy, Buy, Hold and Sell. The performance horizon is two years unless specified and the notional target price is defined as the analysts' valuation for a stock. Strong Buy: >15%/20% for large caps/midcaps, respectively, with high conviction; Buy: >10%/15% for large caps/midcaps, respectively; Hold: Up to +/-10%; Sell: -10% or more; Pankaj Pandey Head Research pankaj.pandey@icicisecurities.com ICICIdirect.com Research Desk, ICICI Securities Limited, 1 st Floor, Akruti Trade Centre, Road No. 7, MIDC, Andheri (East) Mumbai 400 093 research@icicidirect.com ICICI Securities Ltd Retail Equity Research Page 3

ANALYST CERTIFICATION We /I, Sanjay Manyal, MBA (Finance) and Tejashwini Kumari, MBA (Finance), Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. Terms & conditions and other disclosures: ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products. ICICI Securities Limited is a Sebi registered Research Analyst with Sebi Registration Number INH000000990. ICICI Securities is a wholly-owned subsidiary of ICICI Bank which is India s largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ( associates ), the details in respect of which are available on www.icicibank.com. ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securitiesis under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances. This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months. ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction. ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months. ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report. It is confirmed that Sanjay Manyal, MBA (Finance) and Tejashwini Kumari, MBA (Finance), Research Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months. Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report. Since associates of ICICI Securities are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this report. It is confirmed that Sanjay Manyal, MBA (Finance) and Tejashwini Kumari, MBA (Finance), Research Analysts do not serve as an officer, director or employee of the companies mentioned in the report. ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report. Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report. We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. ICICI Securities Ltd Retail Equity Research Page 4